Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4441 AL 4455

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M.

Lancet Neurol. 2017 Feb;16(2):123-134. doi: 10.1016/S1474-4422(16)30331-3. Epub 2016 Dec 10.

PHARMAID study protocol: Randomized controlled trial to assess the impact of integrated pharmaceutical care at a psychosocial intervention on caregiver's burden in Alzheimer's disease or related diseases

Novais T, Moutet C, Delphin-Combe F, Dauphinot V, Colin C, Krolak-Salmon P, Mouchoux C; PHARMAID study group.

Contemp Clin Trials. 2017 Feb;53:137-142. doi: 10.1016/j.cct.2016.12.020. Epub 2016 Dec 19.

Development and Structural Modification of BACE1 Inhibitors

Gu T, Wu WY, Dong ZX, Yu SP, Sun Y, Zhong Y, Lu YT, Li NG.

Molecules. 2016 Dec 22;22(1):4. doi: 10.3390/molecules22010004.

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Penninkilampi R, Brothers HM, Eslick GD.

J Neuroimmune Pharmacol. 2017 Mar;12(1):194-203. doi: 10.1007/s11481-016-9722-5. Epub 2016 Dec 26.

Solanezumab and the amyloid hypothesis for Alzheimer's disease

Le Couteur DG, Hunter S, Brayne C.

BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.

Tacrine: In vivo veritas

Jarrott B.

Pharmacol Res. 2017 Feb;116:29-31. doi: 10.1016/j.phrs.2016.12.033. Epub 2016 Dec 28.

Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions

Dey A, Bhattacharya R, Mukherjee A, Pandey DK.

Biotechnol Adv. 2017 Mar-Apr;35(2):178-216. doi: 10.1016/j.biotechadv.2016.12.005. Epub 2016 Dec 30.

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies

Rygiel K.

Indian J Pharmacol. 2016 Nov-Dec;48(6):629-636. doi: 10.4103/0253-7613.194867.

Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases

Zhang DM, Ye JX, Mu JS, Cui XP.

J Geriatr Psychiatry Neurol. 2017 Jan;30(1):50-59. doi: 10.1177/0891988716673466. Epub 2016 Oct 17.

Amyloid-beta immunotherapy: the hope for Alzheimer disease?

Barrera-Ocampo A, Lopera F.

Colomb Med (Cali). 2016 Dec 30;47(4):203-212.

Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer's Disease with Respect to the Rising Treatment Costs

Klimova B, Maresova P, Kuca K.

Curr Alzheimer Res. 2016;13(11):1249-1258. doi: 10.2174/1567205013666151116142302.

The Human Alzheimer Disease Project: Answering the Call

DeKosky ST, Growdon JH.

JAMA Neurol. 2016 Apr;73(4):373-4. doi: 10.1001/jamaneurol.2015.4512.

Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings

Heßmann P, Seeberg G, Reese JP, Dams J, Baum E, Müller MJ, Dodel R, Balzer-Geldsetzer M.

J Alzheimers Dis. 2016;51(2):545-61. doi: 10.3233/JAD-150835.

Effects of Exercise on Cognition: The Finnish Alzheimer Disease Exercise Trial: A Randomized, Controlled Trial

Öhman H, Savikko N, Strandberg TE, Kautiainen H, Raivio MM, Laakkonen ML, Tilvis R, Pitkälä KH.

J Am Geriatr Soc. 2016 Apr;64(4):731-8. doi: 10.1111/jgs.14059. Epub 2016 Apr 1.

[Changes in drug management of Alzheimer's disease in nursing homes: Impact of the media campaign against specific drugs for Alzheimer's disease]

Petit AE, Mangeard H, Chazard E, Puisieux F.

Encephale. 2017 Feb;43(1):21-26. doi: 10.1016/j.encep.2015.03.006. Epub 2016 Mar 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias